106 related articles for article (PubMed ID: 9177463)
1. Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes.
Vennegoor CJ; Nijman HW; Drijfhout JW; Vernie L; Verstraeten RA; von Mensdorff-Pouilly S; Hilgers J; Verheijen RH; Kast WM; Melief CJ; Kenemans P
Cancer Lett; 1997 Jun; 116(1):93-101. PubMed ID: 9177463
[TBL] [Abstract][Full Text] [Related]
2. A novel algorithm to improve specificity in ovarian cancer detection.
Arjomandi A; Delanoy ML; Walker RP; Binder SR
Cancer Treat Res Commun; 2018; 15():32-35. PubMed ID: 30207285
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Buttitta F; Cosio S; Fanucchi A; Annicchiarico C; Gagetti O; Bevilacqua G; Genazzani AR
Gynecol Oncol; 1999 Jan; 72(1):76-81. PubMed ID: 9889034
[TBL] [Abstract][Full Text] [Related]
4. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
5. The isotype repertoire of antibodies against novel UH-RA peptides in rheumatoid arthritis.
De Winter LM; Geusens P; Lenaerts J; Vanhoof J; Stinissen P; Somers V
Arthritis Res Ther; 2016 Jun; 18(1):130. PubMed ID: 27267896
[TBL] [Abstract][Full Text] [Related]
6. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
[TBL] [Abstract][Full Text] [Related]
7. p53 autoantibodies in the sera, cyst and ascitic fluids of patients with ovarian cancer.
Montenarh M; Harloziñska A; Bar JK; Kartarius S; Günther J; Sedlaczek P
Int J Oncol; 1998 Sep; 13(3):605-10. PubMed ID: 9683801
[TBL] [Abstract][Full Text] [Related]
8. Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer.
Angelopoulou K; Diamandis EP
Eur J Cancer; 1997 Jan; 33(1):115-21. PubMed ID: 9071910
[TBL] [Abstract][Full Text] [Related]
9. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer.
Gadducci A; Ferdeghini M; Buttitta F; Fanucchi A; Annicchiarico C; Prontera C; Bevilacqua G; Genazzani AR
Anticancer Res; 1996; 16(6B):3519-23. PubMed ID: 9042215
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis.
Garziera M; Montico M; Bidoli E; Scalone S; Sorio R; Giorda G; Lucia E; Toffoli G
PLoS One; 2015; 10(10):e0140351. PubMed ID: 26451959
[TBL] [Abstract][Full Text] [Related]
12. The immune complex p53 protein/anti-p53 autoantibodies in the pathogenesis of ovarian serous carcinoma.
Mielczarek-Palacz A; Sikora J; Kondera-Anasz Z; Smycz-Kubańska M; Englisz A; Strzelczyk J; Kabut J
Ginekol Pol; 2020; 91(9):519-253. PubMed ID: 33030731
[TBL] [Abstract][Full Text] [Related]
13. Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers.
Katchman BA; Barderas R; Alam R; Chowell D; Field MS; Esserman LJ; Wallstrom G; LaBaer J; Cramer DW; Hollingsworth MA; Anderson KS
Proteomics Clin Appl; 2016 Jul; 10(7):720-31. PubMed ID: 27121307
[TBL] [Abstract][Full Text] [Related]
14. Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer.
Marx D; Frey M; Zentgraf H; Adelssen G; Schauer A; Kuhn W; Meden H
Cancer Detect Prev; 2001; 25(2):117-22. PubMed ID: 11341346
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma.
Abendstein B; Marth C; Müller-Holzner E; Widschwendter M; Daxenbichler G; Zeimet AG
Cancer; 2000 Mar; 88(6):1432-7. PubMed ID: 10717627
[TBL] [Abstract][Full Text] [Related]
16. Identification of a unique form of p53 in human cord blood associated with the development of maternal autoantibodies.
Yashar CM; Gerçel-Taylor C; Gibb RK; Weeks JW; Taylor DD
Am J Reprod Immunol; 1998 Jun; 39(6):368-75. PubMed ID: 9645267
[TBL] [Abstract][Full Text] [Related]
17. Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer.
Pedersen JW; Gentry-Maharaj A; Fourkala EO; Dawnay A; Burnell M; Zaikin A; Pedersen AE; Jacobs I; Menon U; Wandall HH
Br J Cancer; 2013 Jan; 108(1):107-14. PubMed ID: 23169294
[TBL] [Abstract][Full Text] [Related]
18. p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells.
Vogl FD; Stickeler E; Weyermann M; Köhler T; Grill HJ; Negri G; Kreienberg R; Runnebaum IB
Oncology; 1999 Nov; 57(4):324-9. PubMed ID: 10575320
[TBL] [Abstract][Full Text] [Related]
19. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
20. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue.
Wild CP; Ridanpää M; Anttila S; Lubin R; Soussi T; Husgafvel-Pursiainen K; Vainio H
Int J Cancer; 1995 Jun; 64(3):176-81. PubMed ID: 7622306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]